Bristol-Myers to file for OTC sale of its Pravachol statin

12/13/2004 | Wall Street Journal, The

Bristol-Myers Squibb has taken official action to get FDA approval to sell its cholesterol-lowering Pravachol over the counter, possibly paving the way for OTC versions of other statins. Bristol-Myers faces the loss of its patent on Pravachol in just over a year and OTC sales are seen as opening a new market for the drugs. An FDA advisory panel plans to meet in mid-January on a similar request by Merck for Mevacor.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC